As a front-runner selective inhibitor for the tumor-associated isoform CA IX, and being currently in Phase Ib/II clinical trials, SLC-0111 has been utilized as a lead CAI for the development of novel promising small molecules with selective inhibitory activity toward CA IX, and with good druggability and lead-likeness characters. The gene discussed is CA9; the disease is neoplasm.